{"filing":{"accession_number":"0001193125-26-234890","cik":"0001422142","ticker":"WHWK","company_name":"Whitehawk Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"d32951d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/d32951d8k.htm"},"events":[{"id":9437,"run_id":8276,"accession_number":"0001193125-26-234890","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1079,"accession_number":"0001193125-26-234890","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:22.431971+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1079,"accession_number":"0001193125-26-234890","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:22.431971+00:00","company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","filing_date":"2026-05-21"}]}